第一,不抽烟≠进了保险箱。尤其是东亚女性、有肺癌家族史的朋友,别因为“我不抽烟”就忽略每年的胸部检查。第二,有家族史,主动做“低剂量CT”筛查,而不是胸片。低剂量 CT 能发现还很小的结节,早期肺癌的治愈率可以很高(参考大规模筛查研究,死亡率明显下降)。把它理解成“给肺装个烟雾报警器”。第三,万一确诊,一定做“基因检测”匹配靶向药。今天的非小细胞肺癌,已经有 EGFR、ALK、ROS1 等一连串“可靶”的驱动基因;测出来,就可能从“化疗硬扛”变成“精准关油门”,生活质量天差地别。最后,说句心里话:基因不是用来吓唬自己的,也不是用来“摆烂”的。知道自己的底数,然后该筛的筛、该戒的戒、该测的测——这才是遗传学视角真正想交给你的东西:接纳基因,但不躺平。小骆说遗传 · 用遗传学视角看世界参考文献1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. PMID: 15118125.2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. PMID: 15118126.3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566. PMID: 17329482.4. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancer. J Clin Oncol. 2012;30(8):863-870. PMID: 22693127.5. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. PMID: 21719323.6. Testa U, Castelli G, Pelosi E. Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting. Tumori. 2023. PMID: 37772924.7. Díaz-Gay M, Zhang T, Hoang PH, et al. The mutagenic forces shaping the genomic landscape of lung cancer in never smokers. medRxiv/PubMed. 2024. PMID: 38798417.8. Li J, et al. Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark Res. 2024. PMID: 38347643.